EyePoint Inc (EYPT) FinancialsEYPTFinancialEyePoint Inc

EyePoint Inc (EYPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is YUTIQ, accounting for 91.5% of total sales, equivalent to $9.02M. Another important revenue stream is DEXYCU. Understanding this composition is critical for investors evaluating how EYPT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, EyePoint Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -19207.10%, while the net margin is -18633.14%. These profitability ratios, combined with a Return on Equity (ROE) of -148.70%, provide a clear picture of how effectively EYPT converts its operational activities into shareholder value.

In the context of the broader market, EYPT competes directly with industry leaders such as TKNO and ENTA. With a market capitalization of $1.27B, it holds a leading position in the sector. When comparing efficiency, EYPT's gross margin of 100.00% stands against TKNO's 37.73% and ENTA's 100.00%. Such benchmarking helps identify whether EyePoint Inc is trading at a premium or discount relative to its financial performance.

EyePoint has reported substantial net losses, with a net income of -$94,470,000 in Q2 2026. The gross margin has fluctuated significantly, with a low of 24.14% in Q1 2026, indicating challenges in maintaining profitability. The forward P/E ratio is 6.16, but this is misleading given the company's negative earnings.